Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug for Covid-19. Credit: seksan Mongkhonkhamsao ...

The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set ...

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Twitter by Jack Prescott. In this article, we will ...

General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, "Toripalimab has made significant strides in its ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 22 on December 2, 2024, entitled "Less frequent skin ...

The European Commission (EC) has granted marketing authorisation under exceptional circumstances for InflaRx’s Gohibic ...

IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ...

H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European ...

A study found that some long COVID patients who took Paxlovid saw improvement. But experts said the research isn't enough to ...